{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Autoimmune+Lymphoproliferative+Syndrome+%28ALPS%29",
    "query": {
      "condition": "Autoimmune Lymphoproliferative Syndrome (ALPS)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 11,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Autoimmune+Lymphoproliferative+Syndrome+%28ALPS%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T22:28:30.248Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00068146",
      "title": "Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lymphoproliferative Disorders",
        "Lymphoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2002-09-19",
      "completion_date": "2012-11-26",
      "has_results": false,
      "last_update_posted_date": "2018-07-05",
      "last_synced_at": "2026-07-23T22:28:30.248Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00068146"
    },
    {
      "nct_id": "NCT06730126",
      "title": "Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autoimmune Lymphoproliferative Syndrome"
      ],
      "interventions": [
        {
          "name": "Soquelitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "16 Years to 120 Years"
      },
      "enrollment_count": 15,
      "start_date": "2025-03-10",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-07-23T22:28:30.248Z",
      "location_count": 3,
      "location_summary": "Bethesda, Maryland • Philadelphia, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06730126"
    },
    {
      "nct_id": "NCT01821781",
      "title": "Immune Disorder HSCT Protocol",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immune Deficiency Disorders",
        "Severe Combined Immunodeficiency",
        "Chronic Granulomatous Disease",
        "X-linked Agammaglobulinemia",
        "Wiskott-Aldrich Syndrome",
        "Hyper-IgM",
        "DiGeorge Syndrome",
        "Chediak-Higashi Syndrome",
        "Common Variable Immune Deficiency",
        "Immune Dysregulatory Disorders",
        "Hemophagocytic Lymphohistiocytosis",
        "IPEX",
        "Autoimmune Lymphoproliferative Syndrome",
        "X-linked Lymphoproliferative Syndrome"
      ],
      "interventions": [
        {
          "name": "Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 20,
      "start_date": "2013-04-29",
      "completion_date": "2026-04",
      "has_results": false,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-07-23T22:28:30.248Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01821781"
    },
    {
      "nct_id": "NCT00001350",
      "title": "Study of Autoimmune Lymphoproliferative Syndrome (ALPS)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Benign Lymphoproliferative Disorder"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "Up to 99 Years"
      },
      "enrollment_count": 1200,
      "start_date": "1993-05-13",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-07-23T22:28:30.248Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001350"
    },
    {
      "nct_id": "NCT00392951",
      "title": "Sirolimus for Autoimmune Disease of Blood Cells",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Autoimmune Pancytopenia",
        "Autoimmune Lymphoproliferative Syndrome (ALPS)",
        "Evans Syndrome",
        "Idiopathic Thrombocytopenic Purpura",
        "Anemia, Hemolytic, Autoimmune",
        "Autoimmune Neutropenia",
        "Lupus Erythematosus, Systemic",
        "Inflammatory Bowel Disease",
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 30,
      "start_date": "2006-12",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2019-11-19",
      "last_synced_at": "2026-07-23T22:28:30.248Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00392951"
    },
    {
      "nct_id": "NCT00065390",
      "title": "Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Autoimmune Disease",
        "Lymphatic Disease",
        "Lymphoproliferative Disorder"
      ],
      "interventions": [
        {
          "name": "Pyrimethamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 8,
      "start_date": "2003-07",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-07-23T22:28:30.248Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00065390"
    },
    {
      "nct_id": "NCT01962415",
      "title": "Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Immunodeficiency (PID)",
        "Congenital Bone Marrow Failure Syndromes",
        "Inherited Metabolic Disorders (IMD)",
        "Hereditary Anemias",
        "Inflammatory Conditions",
        "Systemic Juvenile Idiopathic Arthritis (sJIA)",
        "Juvenile Rheumatoid Arthritis (JRA)"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Paul Szabolcs",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "2 Months to 55 Years"
      },
      "enrollment_count": 100,
      "start_date": "2014-02-04",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-07-23T22:28:30.248Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01962415"
    },
    {
      "nct_id": "NCT00605657",
      "title": "Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "ALPS",
        "Hypersplenism",
        "Lymphadenopathy"
      ],
      "interventions": [
        {
          "name": "Valproic Acid",
          "type": "DRUG"
        },
        {
          "name": "CT Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood Sample",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Koneti Rao",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "2 Years to 70 Years"
      },
      "enrollment_count": 6,
      "start_date": "2008-01",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2013-03-21",
      "last_synced_at": "2026-07-23T22:28:30.248Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00605657"
    },
    {
      "nct_id": "NCT04528355",
      "title": "Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Primary Immunodeficiency (PID)",
        "Congenital Bone Marrow Failure Syndromes",
        "Inherited Metabolic Disorders (IMD)",
        "Hereditary Anemias",
        "Inflammatory Conditions"
      ],
      "interventions": [
        {
          "name": "data collection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Paul Szabolcs",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "2 Months to 60 Years"
      },
      "enrollment_count": 50,
      "start_date": "2020-08-20",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-07-23T22:28:30.248Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04528355"
    },
    {
      "nct_id": "NCT02422875",
      "title": "Comparative Autoantibody and Immunologic Cell Marker Study",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Autoimmune Diseases",
        "Lupus Erythematosus, Systemic",
        "Communicable Diseases"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2500,
      "start_date": "2012-08",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-07-23T22:28:30.248Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02422875"
    }
  ]
}